Arbor Biotechnologies
PrivateLast Round
Series C
Mar 18, 2025
Est. Valuation
$575M
Total Funding Raised
$320.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Arbor Biotechnologies is a biotechnology company that develops genomic medicines and gene-editing tools using AI and machine learning to address genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arbor Biotechnologies Comparables
Compare Arbor Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Scribe Therapeutics | 85% | |
| Tessera Therapeutics | 79% | |
| HuidaGene Therapeutics | 79% | |
Arbor Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Mar 18, 2025 | ||||
| Series B | Nov 9, 2021 | ||||
| Series A | Aug 2, 2017 | ||||
| Series A | Jun 1, 2017 |
Secondary Market Activity
Bids, offers, and trades by month
| Operation | Date | Price | Size | Share Class | Structure |
|---|---|---|---|---|---|
BID |
Key People
Founding team and executive leadership
Arbor Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GreatPoint Ventures | Series B |
| S32 | Series B |
| Surveyor Capital | Series C, Series B |
| Janus Henderson Group | Series B |
| Aberdeen Group plc | Series C |
| Temasek | Series C, Series B |
| TCG Crossover | Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 17, 2026
Monthly visitors increased 79% MoM.
- Mar 1, 2026
Lead program ABO-101 enters clinical trials for primary hyperoxaluria type 1.
Arbor Biotechnologies Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Arbor Biotechnologies's valuation, stock price, and market status.